Seelos Therapeutics Inc (SEEL)

[mean gene]

The RayVa study is supposed to start in the fall because that is the time when the most people are troubled with this disease. It is supposed to be at home study. The room temperature device is taking a long time because it has to prove effective after it has been on the shelf for the required time. I agree with you on the adventure on the Fispemifene product. The market is huge;however,Apricus only owned the marketing rights in the U.S.and would have to pay Forendo a royalty on sales. I think Apricus would have partnered to market Fis in the U.S., further reducing the pie. I still think Vitaros is the gem in this basket, a 5+ billion market in the world. A 2+ billion market in the U.S. with only 25% of men diagnosed with E D currently being treated, leaving 75% of those diagnosed with no alternative. A 10% market share with Vitaros users would equate to 500+million, a 10% rolyalty would provide 50+million in revenue. This would be over $.80 eps, at a modest 15/1 would equal $12 a share. This is a very conservative estimate not counting milestone payments of nearly 200 million. Lets say the worst thing happens and it does not get approved in the U.S., then cut everything in half and the share price is @ $6 a share. All of this can happen with the revenue from Vitaros sales and very little cash raise if necessary.